Cerus Corporation Reports 10% Increase in Product Revenue for Q2 2026

Cerus Corporation reported its financial results for the second quarter of 2026, revealing a product revenue of $57.4 million, a 10% increase from $52.4 million in the same period last year. For the first half of 2026, product revenue reached $111.1 million, up 16% from $95.7 million in the first half of 2025. The growth in product revenue was primarily attributed to increased sales volumes of disposable platelet and plasma kits, as well as INTERCEPT Fibrinogen Complex (IFC) sales to U.S. customers. However, government contract revenue decreased by 24% to $5.9 million for the quarter, and by 9% to $12.1 million for the six-month period, largely due to the completion of the FDA agreement in September 2025 and reduced activities under existing BARDA contracts.

The company reported a net loss of $2.9 million for the second quarter, an improvement from a net loss of $5.7 million in the same quarter of 2025. For the first half of 2026, the net loss was $4.6 million, compared to $13.4 million in the prior year. Operating expenses decreased to $37.3 million for the quarter, down from $40.1 million a year earlier, driven by reduced research and development costs. The gross profit margin on product sales was 51% for the second quarter, down from 55% in the same period last year, reflecting increased costs related to tariffs and freight charges.

In terms of operational developments, Cerus reported a total of 201.5 million shares of common stock outstanding as of July 16, 2026. The company continues to focus on expanding its market presence, particularly in the U.S. and Europe, where it has received regulatory approvals for its INTERCEPT Blood System for platelets and plasma. The company is also working on the development of its red blood cell system, which is currently undergoing clinical trials. The completion of these trials and the subsequent regulatory approvals are critical for the company’s growth strategy.

Looking ahead, Cerus anticipates continued growth in product revenue driven by increased market acceptance of the INTERCEPT Blood System and ongoing commercialization efforts. However, the company also faces challenges, including potential delays in regulatory approvals for its red blood cell system and the need for additional funding to support its development activities. The company has entered into new credit agreements to bolster its financial position, but it remains cautious about the impact of macroeconomic conditions, including inflation and geopolitical tensions, on its operations and financial performance.